CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd. announced an Extraordinary General Meeting of Shareholders (EGM) to be held on July 29, 2026, in Tel-Aviv, Israel. The primary agenda item for the EGM is to approve an increase in the company's authorized share capital from 30,000,000 to 500,000,000 ordinary shares. Shareholders of record as of July 9, 2026, are eligible to vote, and the Board of Directors recommends voting "FOR" the proposal.

CollPlant Biotechnologies Ltd. announced a private placement offering, expecting to raise approximately $2.6 million in gross proceeds. The offering includes 7,647,061 ordinary shares (or pre-funded warrants) and accompanying unregistered series A and B warrants, priced at $0.34 per share and accompanying warrants. The company intends to use the net proceeds for general corporate purposes, working capital, funding research and development programs, and evaluating strategic business combinations.

CollPlant Biotechnologies reported a significant decline in Q1 2026 GAAP revenues to $73,000 from $2.1 million in Q1 2025, primarily due to a non-recurring milestone payment last year, resulting in a net loss of $3.1 million, up from $1.5 million. The company is actively engaged in discussions for potential collaborations in medical aesthetics and advancing its next-generation dermal filler platform, securing a patent in Korea. Additionally, CollPlant has initiated a process to evaluate strategic alternatives to maximize shareholder value, alongside implementing cost-cutting measures including a 50% headcount reduction.